LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

NextPoint Therapeutics

NextPoint’s world renowned scientific founders recently discovered a novel checkpoint axis that is independent of PD-1/L1 and is present at high levels in many hard to treat cancers. This revolutionary discovery represents a previously unknown gateway to modulating both the adaptive and innate immune systems to find and destroy cancer cells.

Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer.

  • Detlev Biniszkiewicz Chief Executive Officer